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Abstract 
Allogeneic islet transplantation as a therapy for Type 1 Diabetes (T1D) is restricted by the limited 
availability of donor islets, loss of functional islets during pre-transplantation culture in vitro and 
further extensive loss during the immediate post-transplantation period when islet function and 
survival is compromised by the hypoxic, inflammatory host environment. In the longer term 
pathogenic T cell responses drive autoimmunity and chronic allograft rejection. Experimental studies 
have demonstrated that Mesenchymal Stromal Cells (MSCs) have significant potential to improve the 
outcomes of clinical islet transplantation. This review explores the potential for MSCs and their 
‘secretome’ to influence donor islet cell function and survival, as well as the host niche. We discuss 
the possibility of harnessing the therapeutic benefits of MSCs in a cell-free strategy to offer a well-
defined, cell-free approach to improve the outcomes of clinical islet transplantation.  
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Introduction  
Islet transplantation 
Type 1 diabetes mellitus (T1DM) is an autoimmune disorder in which insulin-secreting pancreatic β-
cells are selectively destroyed. The consequent insulin deficiency results in dysregulation of metabolic 
control with hyperglycemia, hyperlipidemia and ketosis leading to a fatal outcome. People with T1DM 
have been treated by the administration of exogenous insulin since the first successful isolation of 
biologically active insulin in 1921. However, insulin therapy treats the symptoms of T1DM rather than 
offering a cure, and it has become clear over the decades that exogenous insulin often fails to maintain 
tight glycaemic control,  and that the subsequent hyperglycemic excursions are responsible for the 
progressive development of a range of devastating side effects known as “secondary 
complications”[1]. Replacement of the damaged β-cells offers the potential for restoring physiological 
glycemic control and thus avoiding the development of secondary complications. However, pancreas 
transplantation is surgically invasive and associated with significant co-morbidity [2].  An alternative 
is to transplant only the endocrine component of the pancreas - the islets of Langerhans- which 
comprise 2-3 % of the total pancreas, and which can be isolated from the intact pancreas by 
collagenase digestion. Islet transplantation first became a viable therapeutic option with the 
publication of the landmark “Edmonton Protocol” in 2000 [3], which stimulated human islet 
transplantation programmes around the world, such that over 1,500 people with T1DM have now 
received islet grafts in 40 centres globally (https://citregistry.org/content/citr-9th-annual-report). 
Islet transplantation is a safe procedure with little or no co-morbidity [4] and the clinical outcomes 
have improved year-on-year [4,5]. Recent figures suggest that approximately 50 % of graft recipients 
remain insulin independent at 5 years and more, making islet transplantation as clinically effective as 
whole pancreas transplantation [6]. However, the wider adoption of islet transplantation as a 
therapeutic option is currently limited by a shortage of tissue donors and much effort is currently 
directed at generating functionally-competent substitutes for primary human islets to expand the 
available pool of graft material.      
Islet β-cells are metabolically active and use glucose metabolism and ATP generation to maintain 
appropriate rates of insulin secretion for the prevailing extracellular glucose concentrations. Islets 
deteriorate rapidly during and after their isolation [7], losing 20-50 % of the β-cell mass within 24h of 
culture in vitro.  The loss of β-cell function continues during the immediate post-transplantation period 
(24-72h) when up to 70 % of the graft function is lost because of deleterious responses of the 
transplanted β-cells to the hypoxic, inflammatory, immunogenic host environment [8]. Strategies 
which improve the functional survival of islets both before and after transplantation will improve the 
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outcome of individual grafts and enable the limited pool of donor islets to treat many more people 
with T1DM. One emerging strategy is the use of mesenchymal stromal cells (MSCs) to take advantage 
of their anti-inflammatory, immunoregulatory, angiogenic and regenerative properties.   
Mesenchymal stromal cells and islet transplantation   
MSCs are multipotent adult stromal progenitor cells located in the perivascular niche of most adult 
tissues, where they are involved in regeneration and repair in response to tissue ageing or damage. 
Importantly, MSCs can be isolated from their host tissues and maintained and expanded in vitro.  
There is no single specific marker for identifying MSCs, so the International Society for Cellular Therapy 
has specified three essential criteria to define cells as MSCs.  First, cells must be plastic-adherent when 
maintained in standard culture conditions. Second, ≥ 95 % of cells must express CD105, CD73 and 
CD90 but not express the hematopoietic markers CD45, CD34, CD14 or CD11b, CD79α or CD19 and 
HLA class II. Finally, MSCs must be capable of differentiation into osteoblasts, adipocytes and 
chondroblasts in vitro [9]. 
There is accumulating evidence that MSCs can improve the outcomes of islet transplantation in 
experimental models. Thus, co-administration of MSCs improved islet graft function in syngeneic [11-
12, 21], allogenic [13-16] and humanised mouse models [17] and in non-human primate models [18] 
of islet transplantation.  A range of in vitro and in vivo studies suggest that MSCs exert direct effects 
on the islet β-cells to improve their post-transplantation function and survival, and also influence the 
host environment to supress inflammatory innate immune responses [19] and T-cell-dependent 
acquired immunity [20], and to enhance revascularisation of the graft [11-13,21].  
 
Influencing the host environment 
Isolated islets are metabolically fragile because of the stresses (mechanical, enzymatic), loss of 
extracellular matrix (ECM) [22] and ischaemia associated with the isolation process. These fragile islets 
are transplanted into a hostile inflammatory environment leading to further β-cell death [23]. The 
clinically–preferred route for graft delivery via the hepatic portal vein has the advantages of being 
simple, minimally-invasive and targeting insulin to the liver, but intravascular delivery triggers the 
instant blood mediated inflammatory response (IBMIR). This leads to thrombus formation around the 
islets and the initiation of an inflammatory cascade, both of which are deleterious to the islet graft  
[24]. In the longer term, auto- and allo-reactive T cell responses to transplanted islets contribute to 
graft attrition [20], and the metabolically-active β-cells are susceptible to anoxia during the 
revascularisation process [25].     
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Modulating the host immune response  
MSCs can influence cells of the innate and adaptive immune systems and their co-transplantation at 
extrahepatic sites creates an immunosuppressive niche [14]. For example, MSCs influence 
macrophage phenotype by inducing a shift from pro- (M1) to anti-inflammatory (M2) macrophages 
(reviewed in [19]), which reduces graft neutrophil infiltration and inflammation during the immediate 
post-transplantation period. MSCs also have the potential to intercept the priming and amplification 
of autoreactive T cells. Thus, in T1DM MSCs can drive monocyte-derived dendritic cells (DCs) toward 
an immature, IL-10 producing regulatory phenotype via mechanisms dependent on IL-6, TGF-β and 
prostaglandin-E2 (PGE2) production [26]. More chronically, MSCs or multipotent adult progenitor cells 
(MAPCs [27]; off-the shelf clinical grade MSCs) influence cells of the acquired immune system to 
supress pathogenic T cell proliferation [13,28-31] and the production of proinflammatory cytokines, 
whilst favouring a more protective regulatory T cell response and altering the Th1/Th2/Th17 cytokine 
balance [15,20,32,33]. MSC co-transplantation prevents the Th17 immune response in a mouse 
allogeneic model of extrahepatic islet transplantation, but this effect was only observed when MSCs 
were co-delivered with the islets beneath the kidney capsule to create a local immune-privileged site, 
and not when the MSCs were injected systemically (intravenous) [14]. This has implications for 
delivering human islets via the clinically-preferred intraportal route because this will not facilitate the 
co-engraftment of islets and MSCs since their different sizes (~100μm and ~10μm diamater, 
respectively) will  ensure that they lodge in different compartments of the hepatic microcirculation.  
 
An alternative strategy is to identify the key MSC-derived soluble mediators which mediate the 
beneficial effects and use these in a “cell-free” therapeutic capacity.   MSC-derived exosomes [26,34] 
and secreted factors have been shown to contribute to the immunosuppressive properties of MSCs 
(reviewed in [35]),  including matrix metalloprotease 2 (MMP2),  MMP9 [28],  PGE2 [36,37], IDO [32], 
HGF, PDL-1, TGF-β, IL-4 and TSG-6. In addition, we have recently identified a range of MSC-secreted 
ligands for islet G-protein-coupled receptors (GPCRs; [38,39], including Annexin A1 (ANXA1) and 
chemokine (C-X-C motif) ligand (CXCL) 12, which can influence T-cell mediated immune responses.  
CXCL12 repels cytotoxic CD8+ T cells from infiltrating the islet graft whilst attracting  protective 
regulatory T cells, and  coating islets with CXCL12 delays allogeneic graft rejection [40].  Systemic 
administration of ANXA1 delays pro-inflammatory Th17 cell-mediated progression of autoimmune 
uveitis [41,42],  a mechanism that may also be important in reducing Th17-mediated β-cell apoptosis 
in autoimmune T1DM and clinical islet transplantation.  
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Improving revascularisation 
Transplanted islets are avascular during the immediate post transplantation period exposing  β-cells 
to a hypoxic microenvironment [25] which can lead to ischaemic cell death, so enhancing graft 
revascularisation should improve transplantation outcomes. Numerous studies have demonstrated 
that co-transplantation of MSCs [11-13,21] or MAPCs [27] improves islet revascularisation via a range 
of pro-angiogenic factors [12,43]. For example, Cunha and colleagues [27] identified angiogenic 
factors expressed by MAPCs, including vascular endothelial cell growth factor (VEGF-A, -C, and -D), 
placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1) and IL-8, which are likely to 
contribute to enhanced revascularisation. Wnt signalling in MSCs promotes the secretion of pro-
angiogenic proteins as well as matricellular proteins that generate a niche for islet regeneration [44], 
and MSCs secrete Wnt4 and Wnt5a [38]. However, these factors have opposing effects on islet 
endothelial cell survival (EC) with Wnt4 conferring protective effects and Wnt5 detrimental effects 
[45].  Notably, the protective effects of Wnt4 were also associated with reduced expression of vascular 
adhesion molecule 1 (VCAM1) and intercellular adhesion molecule 1 (ICAM1), indicative of reduced 
inflammation in the ECs. Identifying and delivering MSC-derived molecules which enhance islet graft 
revascularisation should improve β-cell survival during the crucial immediate post-transplantation 
period.  
 
Improving graft functional survival 
Several experimental studies have shown that MSCs maintain functional β-cell mass during culture  in 
vitro [46-48], with associated improvements in islet graft function in vivo [46,47], and it is now well  
established that MSCs have direct effects on β-cells to enhance their insulin secretory capacity   [12,46-
49] and protect them from cytokine-induced apoptosis [50]. Direct cell-cell contact plays a role in the 
capacity of MSCs to promote insulin secretory function [46,47,51], with N-cadherin interactions 
maintaining the function of encapsulated islets in diabetic mice [51]. It is well established that ECM 
components exert beneficial effects on the function and viability of islets. Both mouse and human 
MSCs lay down an ECM consisting mainly of collagen 3A1 and 4A1 in vitro [39,52] and MSC-derived 
ECM enhances islet insulin secretory function in vitro [39]. The precise mechanism through which islet-
ECM interactions enhance islet insulin function is unclear but integrin receptors are likely to play a 
role. Integrins are a large family of αβ heterodimeric transmembrane glycoproteins which maintain 
cell adhesion and provide bidirectional signal transduction across the islet cell membrane. Islet-
integrin-ECM binding has been linked to the activation of signalling cascades  components implicated 
in improved islet function and survival, such as PKB/Akt and Erk1/2 [53]. More recently, it has been 
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shown that collagen 3, a common component of ECM,  potentiates insulin secretion by activating β-
cell GPCR 56 [54], which is the most abundantly expressed GPCR in mouse and human islets [55].  
 
Soluble secretory products also play important roles in the beneficial effects of MSCs on islet function.   
[38]. Hypoxic preconditioning of human adipose-derived MSCs has been shown to alter their 
secretome, with associated improvements in human islet function and protection from cytokine-
induced apoptosis [56]. We have demonstrated recently that pre-culturing islets with ANXA1 in vitro 
improved the functional quality of mouse and human islets [38,39] and the outcomes of subsequent 
experimental islet transplantation [38]. We have recently extended these studies to demonstrate that 
a defined ‘cocktail’ of MSC-derived molecules is more effective than ANXA1 alone. Thus, pre-culturing 
mouse islets with a cocktail of three MSC secretory products – ANXA1, SDF-1 and complement 
component C3a - induced persistent improvements in insulin secretion and protection from cytokine-
induced apoptosis for up to 72h after the pre-incubation period (Rackham et al., under review), which 
covers the immediate post-transplantation period when graft survival is compromised [23]. These in 
vitro observations correlate with improved in vivo function of islets which were pre-cultured with the 
cocktail before implantation (Rackham et al., under review). Recent studies suggest that the persistent 
effects of ANXA1, following its removal from the culture media, may be due to the up-regulation of 
the formyl peptide receptor (FPR)2/ALX, PI3K and subsequent downstream pathways including 
activation of pro-survival Akt [57]. Restoration of Akt signalling in the heart and kidney has also been 
demonstrated following treatment with recombinant ANXA1, with associated reductions in the 
development of both cardiac and renal dysfunction, which is typically associated with the underlying 
diabetic phenotype [58]. Thus, MSCs and their ‘secretome’ maintain functional β-cell mass in vitro and 
support islet functional survival after transplantation, with the additional potential to reduce the 
development and progression of secondary microvascular complications.  
 
Conclusion 
There is convincing  experimental evidence that MSCs improve the outcomes of experimental islet 
transplantation and therefore have the potential to improve human islet transplantation as a therapy 
for T1DM. It has become evident that MSCs secrete molecules which have beneficial effects on the 
islet graft and/or on the host environment. Defining a cocktail of MSC secretory factors which 
improves the functional survival of donor islets, enhances their revascularisation and reduces 
inflammatory and pathogenic T cell responses raises the possibility of harnessing the therapeutic 
benefits of MSCs in a cell-free strategy [38,59], avoiding the logistical, safety and regulatory concerns 
of including MSCs in clinical islet transplantation protocols. Schematic 1 shows three potential sites 
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for therapeutic intervention: pre-treating the donor islets with a cocktail of factors to improve 
subsequent functional survival; short-term co-delivery of defined factors to the site of islet 
engraftment, either by pre-coating the islets [40] or by incorporating the factors into polymeric islet 
nanocoatings [60]; and longer-term systemic administration of chosen factors. We suggest that, in 
combination, these approaches offer a well-defined, cell-free approach to improve the outcomes of 
clinical islet transplantation.  
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Figure Legend 
 
Figure 1: Schematic for proposed delivery of MSC-derived secretory products during the islet 
transplantation procedure. Based on experimental studies, we propose a tripartite strategy for using 
MSC secretory products to improve islet transplantation outcomes.  
 
1. Preculture islets in vitro with a defined cocktail of soluble MSC-derived secretory products for 
24-48h before transplantation to enhance subsequent graft function. 
2. Co-delivery of defined MSC-derived secretory products with the islet graft will ensure localised 
effects on graft and host niche in vivo, during the early post-transplantation period (7-14 days 
post-transplantation). 
3. Systemic delivery of MSC-derived secretory products will enable sustained effects of MSC-
biotherapeutics in vivo.  
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